John Gerecitano, MS; Alvin Friedman-Kien, MD; Geoffrey D. Chazen, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Gerecitano J., Friedman-Kien A., Chazen G.; Allergic Reaction to Varicella Vaccine. Ann Intern Med. 1997;126:833-834. doi: 10.7326/0003-4819-126-10-199705150-00036
Download citation file:
Published: Ann Intern Med. 1997;126(10):833-834.
TO THE EDITOR:
Two weeks after inoculation with the varicella virus vaccine (Varivax, Merck and Co., Inc., West Point, Pennsylvania), a 26-year-old healthy man who was seronegative for human immunodeficiency virus noticed a 2.0-cm oval-shaped macule on the skin of his left axilla. Ten days after onset of the eruption, about 50 such lesions were counted on the trunk, concentrated in the axillary regions (not at the vaccination site). The pink-red lesions were nonblanching and had a darker red border. The results of punch biopsy were nondiagnostic.
During the next 6 weeks, the macular lesions gradually faded as reddish, 1- to 2-mm petechiae developed in about the same distribution (Figure 1). These lesions spread over the trunk, neck, and extremities bilaterally, sparing the face, palms, soles, and oral mucosa. A 2-week course of 0.5% fluocinonide cream twice daily, started after 22 days, was ineffective. A complete blood count done 34 days after onset revealed a low platelet count (114 × 109/L), slightly decreased hematocrit (0.393) and leukocyte count (3.7 × 109/L), and normal differential.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only